pharma · BIOCON

Biocon

Biocon: PE above historical average. NARROW LEADERSHIP regime. sector leading.

Price

₹425.35

Price 2026-07-30

5 day

-1.91%

Short-term move

1 month

+1.81%

Medium-term

Regime

NARROW LEADERSHIP

62% confidence

Market cap

₹66.3k Cr

inflow sector flow

Market Intelligence Analyst

Understand today's market in about 2 minutes.

How does today's NARROW LEADERSHIP regime affect Biocon (BIOCON) in the pharma sector?

Ask about this stock

Price chart

432

+21.74% over period

2025-06-30331 – ₹4442026-07-28

About Biocon

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

BiotechnologyBengaluru, India16,447 employeesWebsite →

At a Glance

ValuationPE 145.3 (57%ile of 7 quarterly points (limited history), range 30-342). Trading near median.
Sector Positionpharma sector. Flow: inflow. is in the leaders group. Regime: NARROW LEADERSHIP (62%).
Historical ContextRSI oversold bounces for this stock succeeded only 0% of the time (avg -9.2% over 14 days) — not a reliable pattern.
Revenue TrendRevenue growing at 230.0% YoY. Strong revenue growth — 230.0% YoY

RSI pattern warning

RSI oversold bounces for this stock succeeded only 0% of the time (avg -9.2% over 14 days) — not a reliable pattern.

52-week position

Trading at 96.6% of 52-week high

52W low ₹33152W high ₹440.4

Technicals

RSI 14

54.8

Trend

uptrend

50 DMA

Above

200 DMA

Above

Key metrics

P/E ratio

145.3

57th pct · 7 quarterly points (limited history)

P/B

1.9

ROE

1.1%

Below-average profitability — 1.1% ROE

Market cap

₹66.3k Cr

Revenue growth

230.0% YoY

Promoter

53.8%

52-week range

₹331 – ₹440.4

96.6% of high

RSI (14)

54.8

uptrend

vs 50 DMA

Above

DMA ₹422.47

Coverage

100/100

HIGH

Quick Take

Biocon: PE above historical average. NARROW LEADERSHIP regime. sector leading.

Peer comparison

StockPrice5DP/EROERev growthMcap
DIVISLAB

Divi's Laboratories

₹7,835+7.7%7016.2%950%₹1.8L Cr
CIPLA

Cipla

₹1,466.4+5.3%30.211.7%-210%₹1.2L Cr
DRREDDY

Dr. Reddy's Laboratories

₹1,144.8-1.8%26.511.8%-1160%₹1.1L Cr
AUROPHARMA

Aurobindo Pharma

₹1,576.3+3.5%26.39.9%560%₹91.1k Cr
ALKEM

Alkem Laboratories

₹5,816.5+3.8%29.417.6%1460%₹67.8k Cr
GLENMARK

Glenmark Pharmaceuticals

₹2,190.3-0.7%4714.1%1430%₹63.9k Cr
GLAND

Gland Pharma

₹2,517+5.9%40.910.5%2230%₹42.1k Cr
JBCHEPHARM

J B Chemicals

₹2,408.9+0.0%54.518.7%-480%₹38.9k Cr
BIOCON

Biocon

₹425.35-2.3%145.31.1%230%₹66.3k Cr

Tensions to watch

Promoter holding at 53.8% — neither distress selling nor aggressive buying

No strong insider signal. Watch for changes in promoter stake as a leading indicator.

Key Watchpoints

🟢

Breaks above ₹447 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹404 (-5%)

Further downside risk

🟡

PE reverts to median of 131.2 (7 quarterly points (limited history))

Valuation normalization

🟢

Pharma sector holding leadership position

Sector momentum continuing

Facts

P/E Ratio
145.3MODERATE
P/B Ratio
1.9HIGH
ROE
115.0%HIGH
Market Cap
₹6625527.1L CrHIGH
From 52W High
97% of high
Promoter Holding
53.8%MODERATE
Institutional
26.2%
Sector Peers
10
FinGenieFinGenie

Understand today's market in about 2 minutes. Ask your analyst